Lyon: JD Health's third quarter revenue increased by 25% year-on-year, raising the target price to HK$66.

According to the Sina Finance app, Lyon released a research report stating that it has raised its forecast for JD Health's (06618.HK) full-year revenue growth in 2025 to 22%, with an estimated Ebit profit margin of 5.7% (up from the original forecast of 5.0%); the company's adjusted net profit forecast for the next two years has also been raised by 5% and 4%, and the target price has been raised from HK$64 to HK$66, with a reiterated "outperforming the market" rating.